- Home
- IMOS vs VRDN Comparison
IMOS vs VRDN Comparison
Compare IMOS & VRDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | IMOS | VRDN |
|---|---|---|
| Founded | 1997 | 2006 |
| Country | Taiwan | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Medical Specialities |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.4B |
| IPO Year | 2007 | 2014 |
Fundamental Metrics
Financial Performance| Metric | IMOS | VRDN |
|---|---|---|
| Price | $48.33 | $17.59 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 14 |
| Target Price | N/A | ★ $35.46 |
| AVG Volume (30 Days) | 85.2K | ★ 3.0M |
| Earning Date | 05-14-2026 | 05-07-2026 |
| Dividend Yield | ★ 1.51% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $5,706,000.00 |
| Revenue This Year | $21.75 | $13.73 |
| Revenue Next Year | $4.21 | $279.00 |
| P/E Ratio | $158.35 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $15.06 | $13.18 |
| 52 Week High | $61.27 | $34.29 |
Technical Indicators
Market Signals| Indicator | IMOS | VRDN |
|---|---|---|
| Relative Strength Index (RSI) | 48.63 | 53.11 |
| Support Level | $32.65 | $15.68 |
| Resistance Level | $51.08 | $19.72 |
| Average True Range (ATR) | 1.96 | 0.99 |
| MACD | -0.94 | 0.39 |
| Stochastic Oscillator | 18.79 | 60.80 |
Price Performance
Historical ComparisonAbout IMOS ChipMOS TECHNOLOGIES INC.
ChipMOS TECHNOLOGIES Inc is engaged in the research, development, manufacturing, and sale of high-integration and high-precision integrated circuits and related assembly and testing services. The company's segments include Testing, Assembly, Testing, and Assembly for LCD, OLED, and other Display Panel Driver Semiconductors (LCDD), Bumping, and others. It derives a majority of its revenue from Taiwan followed by Japan, the People's Republic of China, Singapore, and others.
About VRDN Viridian Therapeutics Inc.
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. The company is developing two anti-IGF-1R product candidates, veligrotug for intravenous (IV) administration and elegrobart (formerly VRDN-003) for subcutaneous (SC) administration, to treat patients with TED. Our most advance program, veligrotug, is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of TED.